Publications by authors named "Paul A Kudlow"
Article Synopsis
- The default mode network (DMN) is a group of brain regions activated during rest and spontaneous thoughts, but quiet during focused tasks.
- Research shows the DMN is linked to self-awareness and emotional processing, integrating internal thoughts with external information to shape our self-concept.
- There is evidence of DMN irregularities in various neuropsychiatric and metabolic disorders, but more research is needed to understand how these changes may increase the risk for neuropsychiatric issues and how they could influence treatment approaches.
Studies have found that up to two-thirds of patients with major depressive disorder (MDD) do not fully respond to the first antidepressant. While switching antidepressants is a common strategy for antidepressant non-responders, there is still a lack of consensus about the optimal timing of a switch. Many clinicians wait for 6-12 weeks before considering a switch.
View Article and Find Full Text PDFArticle Synopsis
- Cognitive enhancing agents can improve memory, attention, concentration, and intelligence.
- An online survey sent to 647 medical students in Canada revealed a 50% response rate, with 15% admitting to non-medical use of pharmaceutical stimulants.
- Senior students and male participants showed a higher likelihood of stimulant use and more positive attitudes toward cognitive enhancers.
Schizophrenia is a heterogeneous and complex mental disorder with high rates of disability, non-recovery, and relapse. The primary pharmacological treatments for schizophrenia are antipsychotics. Notwithstanding the efficacy of antipsychotics in ameliorating positive symptoms and reducing relapse rates, cognitive deficits and negative symptoms are not sufficiently treated with available pharmaceutical agents.
View Article and Find Full Text PDFObjective: Antidepressants (ADs) are the mainstay of treatment for major depressive disorder (MDD). Despite their widespread usage, a consensus does not exist as to the timing of clinically significant symptomatic improvement during an AD trial. The objective of this review is to provide practitioners with empirically based recommendations pertaining to the optimal duration of index (initial) AD therapy before a clinical intervention is warranted.
View Article and Find Full Text PDF